fws
Specials
David Feldman quoted in Financial Week about reverse mergers on July, 14, 2008.
More>>
March 18, 2009
Securities and Regulation Committee

Association of the Bar of the City of New York
More>>
 
fws
David Feldman's book, Reverse Mergers: Taking a Company Public Without an IPO, now in its third printing, was published in 2006 by Bloomberg Press (available on http://www.amazon.com). View David Feldman's reverse merger blog at www.reversemergerblog.com.
fws
Joseph Smith and David Feldman are coauthors of PIPES: Revised and Updated Edition - A Guide to Private Investments in Public Equity (Bloomberg Press, 2005) available on http://www.amazon.com.
 

Life Science VC Firm Forms Virgin Shell

The Reverse Merger Report (May 8, 2008)

 

MPM Asset Management, a Boston-based venture capital firm focused on life sciences, recently created a Form-10 shell company with the assistance of the New York law firm of Feldman Weinstein & Smith.  The formation is indicative of a growing interest by venture capital firms in shell merger transactions.

The shell, called MPM Acquisition Corp., has 5 million shares outstanding.  They are controlled by Steven St. Peter, MPM Acquisition’s president and a general partner at MPM Asset Management, and Ansbert Gadicke, also an MPM general partner.

MPM Asset has sold two previous portfolio companies to SPACs.  In December 2006, it sold medical device maker Alsius Corp. to the $53 million SPAC Ithaka Acquisition Corp. for $97 million.  In August 2007, it sold biodefense pharmaceutical maker PharmAthene to the $75 million SPAC Healthcare Acquisition Corp. for $112.5 million.  St. Peter currently sits on PharmAthene’s board.

MPM Asset did not return calls for comment.

Registration filings by MPM Acquisition make no specific mention of using the shell for exiting a portfolio investment; however, securities attorneys note budding interest from venture capital and private equity firms in reverse merger transactions.  The firms have been some of the last to embrace shell mergers.

“The growing interest in SPACs as an exit strategy will hopefully lead to a greater interest in traditional reverse mergers,” David Feldman, a founding partner with Feldman Weinstein & Smith, said.  “The greatest hurdle is realizing that the market price builds over time.  The reverse merger is not the exit, but a step in that direction.”

With a virtually dormant IPO market, Feldman said the shell merger route should start to become more attractive.  Two years ago exit strategies were split 50-50 between acquisitions and IPOs.  Now, it is closer to 90-10, he said.

Additionally, venture capital geared towards pharmaceutical and biotech companies has been quicker to consider shell mergers, especially for pre-revenue companies in the Phase II trial stage, according to Feldman.  There are greater financing options available for early-stage startups and late-stage operations close to market.  For those companies still two or more years away, it can be a bit more difficult, he said.

fws

Disclaimer: The information on this site does not convey legal advice of any kind. The transmission of this web site or communication with Feldman Weinstein & Smith via Internet e-mail does not by itself constitute or create an attorney-client relationship between Feldman Weinstein & Smith and any party. Any information sent to Feldman Weinstein & Smith via Internet e-mail or through this web site is not secure and is done so on a non-confidential basis.
Attorney advertising is contained on this website.
©2008 Feldman Weinstein & Smith LLP